Data show many patients discontinue or switch treatment within the first year ...

Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.

ASH and ISTH sought to develop clinical practice guidelines on anticoagulant prophylaxis for pediatric patients who are at risk of VTE.

Italy: Researchers have discovered in a new research that among patients with Hemophilia A, prophylaxis with Mim8 was ...

Mim8 prophylaxis significantly reduced bleeding events in patients with or without inhibit ...

The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa ...

Cancer patients face a high risk for infection when undergoing cytotoxic chemotherapy and hematopoietic stem cell transplant (HSCT), particularly during the period of neutropenia. In this high-risk ...

Recommendations for anticoagulant prophylaxis for pediatric patients at risk for venous thromboembolism (VTE) have been presented.

When the World Health Organization endorsed twice-yearly lenacapavir as a new option for HIV pre-exposure prophylaxis, much ...

Previous reports suggest a benefit of fluconazole prophylaxis in extremely low birth weight (ELBW) infants <1000 g. Our aim was to evaluate if limiting fluconazole prophylaxis to targeted highest risk ...

Awareness of venous thromboembolism has increased considerably. As a result of the Surgeon General's call to action in 2008 to prevent deep-vein thrombosis and pulmonary embolism, programs have been ...